Therapies – discovery and development
C126 – C169
- C126: Image based pathway analysis of FOXO regulation leads to the discovery of therapeutic targets and small molecule inhibitors for anticancer therapy
- C127: Antigenic modulation of rituximab results in its rapid consumption in vivo and limits its ability to deplete target B cells
- C128: The role of activatory and inhibitory FcgR in antibody immunotherapy
- C129: Abstract withdrawn
- C130: T cell receptor gene transfer to target the Epstein-Barr virus-associated malignancy nasopharyngeal carcinoma
- C131: A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer
- C132: Does paclitaxel chemotherapy cause long-term arthralgia? Results of a focussed questionnaire in ovarian cancer patients on follow-up
- C133: Engineering and characterisation of a b aculovirus-expressed m ouse/ human chimeric antibody against transferrin receptor on the surface of human tumour cells
- C134: Identification of a human antibody 3.19.3 that inhibits ANG-2 function leading to significant anti-tumour activity, both alone and in combination with VEGF inhibitors, in a panel of tumour xenograft models
- C135: Mustard blood partition: differences between rodents and cancer patients, and the consequences for anticancer drug development
- C136: Development of allo-restricted cytotoxic T cell specific for TWIST – a potential novel target for cancer immunotherapy of childhood cancers
- C137: High-throughput screen for small molecule inhibitors of DNA mismatch repair
- C138: Development of human apurinic/apyrimidinic endonuclease (APE1) inhibitors for cancer therapy
- C139: Identification and characterisation of small molecule inhibitors of phosphatidylinositol-4-phosphate 5-kinase
- C140: Small molecule inhibitors of the transmembrane receptor tyrosine kinase Axl as potential anti-cancer therapeutics
- C141: Pharmacokinetic and pharmacodynamic phase I trial of ARQ197 incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition
- C142: A first in human phase I study of JNJ26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumours: early evidence of anti-tumour activity
- C143: Safety and feasibility of serial tumour biopsies in phase I clinical trials: the Royal Marsden Hospital Drug Development Unit experience
- C144: Rationally designed bifunctional bisphosphonates for the detection and radionuclide therapy of bone metastases
- C145: A phase-I study of the combination of intravenous reovirus (REOLYSIN ®) and gemcitabine in patients with advanced cancer
- C146: PAX3 function in embryonic cell lines undergoing different differentiation pathways and their corresponding tumours.
- C147: A template for development of a policy for access to data and/or biological samples
- C148: Development of core outcomes sets to be reported in clinical trials for curative treatment of upper gastrointestinal cancer: a systematic review of the literature
- C149: The efficacy of MEK-inhibitor treatment of B-Raf mutant tumours requires Bim and is enhanced by the BH3-mimetic ABT-737
- C150: Loss of a FOX03A-dependent cell cycle checkpoint for DNA replication origins s ensitises cancer cells to CDC7 inhibitors
- C151: A fully human antibody that inhibits the integrin avb6 reduces tumour growth and modulates key biomarkers
- C152: Abstract withdrawn
- C153: The synthesis of novel G-quadruplex ligands and Host-Guest binding evaluation using DOSY NMR
- C154: Interferon producing killer dendritic cells (IKDC) migrate into tumours and cross present antigens in vitro and in vivo
- C155: Molecular dissection of blood vessel growth and maturation during angiogenesis
- C156: Recombinant human vascular endothelial growth factor (rhVEGF165b) as a therapeutic dose for heterotopic human colon cancer in mice
- C157: A patient RCC-derived murine xenograft model allows better prediction of treatment responses to molecular targeted therapy in patients with advanced renal cancer
- C158: Sequence-dependent strategies for the optimisation of combinations of PI3K pathway inhibitors and classical anticancer agents
- C159: Expression of Eag1 and HERG potassium channels in ovarian cancer
- C160: Cytotoxicity of a protodioscin rich fraction from fenugreek seeds against human cancer cell lines
- C161: Combining inhibitors of the mTOR (AZD8055) and MEK1/2 (AZD6244; ARRY-142886) pathways demonstrates enhanced apoptotic signalling and tumour growth inhibition in human tumour xenograft models
- C162: Identification of novel STAT3 inhibitors
- C163: Induction of thrombospondin-1 mediates the anti-angiogenic activity of dexrazoxane
- C164: Comparing the immune response to radiation-induced tumour cell death with pure apoptosis using a Doxycycline-dependent caspase 3 death switch model
- C165: Effect of anti-CTLA4 (tremelimumab) on the immunomodulatory activity of t regulatory cells
- C166: Rho-GTPase signaling and the vascular disrupting activities of combretastatin A-4-phosphate
- C167: Homologous recombination and ovarian cancer: role of developing a functional assay
- C168: Novel anticancer drug combinations exploiting arginine depletion with ADI-PEG 20 in the treatment of ASS1-negative malignant mesothelioma
- C169: Use of green fluorescent protein (GFP)-imaging to visualise in vivo responses to the anti-tumour agent TRAIL
